S.T. Kim

1.1k total citations
20 papers, 403 citations indexed

About

S.T. Kim is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Surgery. According to data from OpenAlex, S.T. Kim has authored 20 papers receiving a total of 403 indexed citations (citations by other indexed papers that have themselves been cited), including 14 papers in Pulmonary and Respiratory Medicine, 13 papers in Oncology and 5 papers in Surgery. Recurrent topics in S.T. Kim's work include Gastric Cancer Management and Outcomes (8 papers), Colorectal Cancer Treatments and Studies (7 papers) and Cancer Immunotherapy and Biomarkers (4 papers). S.T. Kim is often cited by papers focused on Gastric Cancer Management and Outcomes (8 papers), Colorectal Cancer Treatments and Studies (7 papers) and Cancer Immunotherapy and Biomarkers (4 papers). S.T. Kim collaborates with scholars based in South Korea, United Kingdom and United States. S.T. Kim's co-authors include S.-H. Lee, Seo‐Young Park, Byoung Chul Cho, Jin Seok Ahn, Myung‐Ju Ahn, Jong‐Mu Sun, K. Park, Jin Hyoung Kang, K.H. Lee and Won Ki Kang and has published in prestigious journals such as Annals of Oncology, European Journal of Cancer and Transfusion.

In The Last Decade

S.T. Kim

18 papers receiving 400 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
S.T. Kim South Korea	9	281	210	110	98	42	20	403
James D. Peyton United States	10	200 0.7×	145 0.7×	175 1.6×	61 0.6×	26 0.6×	27	363
Giulia Grizzi Italy	12	262 0.9×	185 0.9×	82 0.7×	41 0.4×	30 0.7×	24	370
Shiaowen David Hsu United States	10	181 0.6×	122 0.6×	102 0.9×	69 0.7×	18 0.4×	37	313
Ritika Kundra United States	7	182 0.6×	147 0.7×	289 2.6×	96 1.0×	23 0.5×	22	539
Michihiro Ono Japan	13	197 0.7×	163 0.8×	119 1.1×	168 1.7×	62 1.5×	24	371
Maria Alessandra Calegari Italy	10	220 0.8×	109 0.5×	89 0.8×	56 0.6×	23 0.5×	43	361
Alexander G. Raufi United States	11	275 1.0×	140 0.7×	156 1.4×	111 1.1×	61 1.5×	36	457
Zhongli Zhan China	11	178 0.6×	223 1.1×	78 0.7×	56 0.6×	62 1.5×	23	361
Audrey Hennequin France	11	410 1.5×	154 0.7×	106 1.0×	102 1.0×	195 4.6×	34	561
S-A Im South Korea	5	246 0.9×	158 0.8×	75 0.7×	42 0.4×	73 1.7×	19	326

Countries citing papers authored by S.T. Kim

Since Specialization

Citations

This map shows the geographic impact of S.T. Kim's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by S.T. Kim with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites S.T. Kim more than expected).

Fields of papers citing papers by S.T. Kim

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by S.T. Kim. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by S.T. Kim. The network helps show where S.T. Kim may publish in the future.

Co-authorship network of co-authors of S.T. Kim

This figure shows the co-authorship network connecting the top 25 collaborators of S.T. Kim. A scholar is included among the top collaborators of S.T. Kim based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with S.T. Kim. S.T. Kim is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Kim, Tae Won, Jung-Il Lee, Sang Joon Shin, et al.. (2023). 661MO Anti-tumor activity of belvarafenib in combination with cobimetinib in patients with metastatic solid tumors harboring BRAF fusions or BRAF class II/III mutation. Annals of Oncology. 34. S465–S466.

Kim, Tae Won, Kyung-Woo Lee, Joong Bae Ahn, et al.. (2023). 618P Efficacy and safety of vactosertib and pembrolizumab combination in patients with previously treated microsatellite stable metastatic colorectal cancer. Annals of Oncology. 34. S443–S443. 3 indexed citations

Lee, Kyung-Woo, Y-K. Kang, M-H. Chen, et al.. (2023). 146P Phase (ph) Ib results of bemarituzumab (BEMA) added to capecitabine/oxaliplatin (CAPOX) or S-1/oxaliplatin (SOX) with or without nivolumab (NIVO) for previously untreated advanced gastric/gastroesophageal junction cancer (G/GEJC): FORTITUDE-103 study. Annals of Oncology. 34. S1530–S1530. 1 indexed citations

Jo, Hyunji, Hong-Sik Kim, Jung Yong Hong, et al.. (2022). A Comparison of Folinic Acid, Fluorouracil and Irinotecan (FOLFIRI) plus Bevacizumab and FOLFIRI plus Aflibercept as Second-line Treatment for Metastatic Colorectal Cancer. Clinical Oncology. 34(8). e323–e328. 2 indexed citations

Catenacci, Daniel V.T., Byoung Yong Shim, S.T. Kim, et al.. (2021). 1379P Margetuximab (M) with retifanlimab (R) in HER2+, PD-L1+ 1st-line unresectable/metastatic gastroesophageal adenocarcinoma (GEA): MAHOGANY cohort A. Annals of Oncology. 32. S1043–S1044. 13 indexed citations

Kwon, Minsuk, Minae An, S.T. Kim, et al.. (2021). Phase II study of ceralasertib (AZD6738) in combination with durvalumab in patients with advanced/metastatic melanoma who have failed prior anti-PD-1 therapy. Annals of Oncology. 33(2). 193–203. 81 indexed citations

Kim, T.W., Sang Joon Shin, Seung Woo Han, et al.. (2021). 529P A phase Ib trial of belvarafenib in combination with cobimetinib in patients (pts) with RAS- or RAF- mutated (m) solid tumors: Updated safety data and indication-specific efficacy results. Annals of Oncology. 32. S595–S595. 7 indexed citations

Byeon, Seonggyu, et al.. (2021). Molecular profiling of Asian patients with advanced melanoma receiving check-point inhibitor treatment. ESMO Open. 6(1). 100002–100002. 18 indexed citations

Park, Seo‐Young, S.T. Kim, Jin Hyoung Kang, et al.. (2020). A phase II, multicenter, two cohort study of 160 mg osimertinib in EGFR T790M-positive non-small-cell lung cancer patients with brain metastases or leptomeningeal disease who progressed on prior EGFR TKI therapy. Annals of Oncology. 31(10). 1397–1404. 122 indexed citations

10.

Kim, S.T., Ju-Bin Kang, Hyun Woo Lee, et al.. (2019). Capecitabine plus oxaliplatin versus gemcitabine plus oxaliplatin as first-line therapy for advanced biliary tract cancers: a multicenter, open-label, randomized, phase III, noninferiority trial. Annals of Oncology. 30(5). 788–795. 75 indexed citations

11.

Sundar, Raghav, Kie Kyon Huang, Aditi Qamra, et al.. (2019). Epigenomic promoter alterations predict for benefit from immune checkpoint inhibition in metastatic gastric cancer. Annals of Oncology. 30(3). 424–430. 39 indexed citations

12.

Cho, Jungwan, Sun Young Kim, Y. J. Kim, et al.. (2017). Emergence of CTNNB1 mutation at acquired resistance to KIT inhibitor in metastatic melanoma. Clinical & Translational Oncology. 19(10). 1247–1252. 10 indexed citations

13.

Kilgour, Elaine, Helen K. Angell, K.-M. Kim, et al.. (2016). Programmed death-ligand 1 (PD-L1) and immune infiltrates are prognostic for better outcome and enriched in the ATM (ataxia telangiectasia mutated)-low segment of gastric cancer (GC). Annals of Oncology. 27. vi212–vi212. 1 indexed citations

14.

Yoo, Keon Hee, S.H. Park, S.T. Kim, et al.. (2015). P-104 Multi-center phase III trial of Adjuvant Chemoradiotherapy in Stomach Tumors 2 (ARTIST 2). Annals of Oncology. 26. iv29–iv29. 1 indexed citations

15.

Kang, Jung Hun, Joo-Hark Yi, In Gyu Hwang, et al.. (2015). P-057 A retrospective analysis for patients with HER2 positive gastric cancer who were treated with trastuzumab-based chemotherapy. Annals of Oncology. 26. iv16–iv16. 1 indexed citations

16.

Kim, S.T., et al.. (2015). 2318 Prospective phase II trial of pazopanib plus CapeOX (capecitabine and oxaliplatin) in previously untreated patients with advanced gastric cancer. European Journal of Cancer. 51. S438–S439. 1 indexed citations

17.

Kim, S.T., In‐Gu Do, Joo‐Heung Lee, et al.. (2014). The NanoString-based multigene assay as a novel platform to screen EGFR, HER2, and MET in patients with advanced gastric cancer. Clinical & Translational Oncology. 17(6). 462–468. 12 indexed citations

18.

Shin, Byung Seop, Woo Seog Sim, S.T. Kim, et al.. (2012). A Comparison of the Effects of Preanesthetic Administration of Crystalloid Versus Colloid on Intrathecal Spread of Isobaric Spinal Anesthetics and Cerebrospinal Fluid Movement. Obstetric Anesthesia Digest. 32(2). 112–112. 1 indexed citations

19.

Kim, S.T., et al.. (2010). Evaluation of a new cell separator for collection of peripheral blood CD34+ progenitor cells in pediatric patients. Transfusion. 51(2). 306–312. 11 indexed citations

20.

Kim, S.T., Ji Young Park, Jun Ho Lee, et al.. (2010). The Efficacy of the Frontline Platinum-based Combination Chemotherapy in Malignant Peritoneal Mesothelioma. Japanese Journal of Clinical Oncology. 40(11). 1031–1036. 4 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact